No Data
No Data
Morgan Stanley Maintains Sophia Genetics(SOPH.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BTIG Maintains Sophia Genetics(SOPH.US) With Buy Rating, Maintains Target Price $5
Blood Cancer Diagnostics Market Analysis Report 2025-2030, With Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics
BTIG Maintains Sophia Genetics(SOPH.US) With Buy Rating, Cuts Target Price to $5